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Background: Administration of androgens decreases plasma concentrations of high-density lipid cholesterol
(HDL-C). However, the mechanisms by which androgens mediate lipid metabolism remain unknown. This present
study used HepG2 cell cultures and ovariectomized C57BL/6 J mice to determine whether apolipoprotein M
(ApoM), a constituent of HDL, was affected by dihydrotestosterone (DHT).
Methods: HepG2 cells were cultured in the presence of either DHT, agonist of protein kinase C (PKC),
phorbol-12-myristate-13-acetate (PMA), blocker of androgen receptor flutamide together with different
concentrations of DHT, or DHT together with staurosporine at different concentrations for 24 hrs. Ovariectomized
C57BL/6 J mice were treated with DHT or vehicle for 7d or 14d and the levels of plasma ApoM and livers ApoM
mRNA were measured. The mRNA levels of ApoM, ApoAI were determined by real-time RT-PCR. ApoM and ApoAI
were determined by western blotting analysis.
Results: Addition of DHT to cell culture medium selectively down-regulated ApoM mRNA expression and ApoM
secretion in a dose-dependent manner. At 10 nM DHT, the ApoM mRNA levels were about 20% lower than in
untreated cells and about 40% lower at 1000 nM DHT than in the control cells. The secretion of ApoM into the
medium was reduced to a similar extent. The inhibitory effect of DHT on ApoM secretion was not blocked by the
classical androgen receptor blocker flutamide but by an antagonist of PKC, Staurosporine. Agonist of PKC, PMA, also
reduced ApoM. At 0.5 μM PMA, the ApoM mRNA levels and the secretion of ApoM into the medium were about
30% lower than in the control cells. The mRNA expression levels and secretion of another HDL-associated
apolipoprotein AI (ApoAI) were not affected by DHT. The levels of plasma ApoM and liver ApoM mRNA of
DHT-treated C57BL/6 J mice were lower than those of vehicle-treated mice.
Conclusions: DHT directly and selectively down-regulated the level of ApoM mRNA and the secretion of ApoM by
protein kinase C but independently of the classical androgen receptor.
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Men exhibit a higher incidence of cardiovascular dis-
eases than women, and men have lower circulating levels
of antiatherogenic high-density lipoprotein cholesterol
((HDL-C). Evidence indicates that the cardiovascular
actions of sex steroids are primary factors in mediating
this gender-related difference. Because androgen admin-
istration lowers HDL-C levels in both genders [1], par-
ticularly at supraphysiological plasma concentrations,
endogenous androgens, such as testosterone, have been
implicated in influencing the lipoprotein profile and risk
for cardiovascular diseases (CVD). However, the rela-
tionship between androgens and lipid metabolism CVD
risk factors is highly complex, and the results of different
studies are contradictory [2]. A likely explanation for the
complex relationship between androgens and CVD is that
androgens affect many risk factors. For example, andro-
gens can increase muscle mass, decrease visceral fat mass
in some subjects, improve coronary blood flow, increase
mood and motivation (perhaps leading indirectly to health
benefits), reduce lipoprotein (a) and leptin, improve insu-
lin sensitivity, and provide other potential benefits, such as
anti-inflammatory effects [3]. To understand the role of
endogenous and therapeutic androgens in CVD, it will be
necessary to identify the mechanisms responsible for the
changes in HDL-C levels.
Apolipoprotein M (ApoM) is mainly expressed by hepa-
tocytes and tubular epithelial cells in the kidney and is
associated mainly with high-density lipoprotein (HDL) in
human plasma [4-7]. Mice deficient in ApoM are impaired
in their ability to produce preβ-HDL. Further, overexpres-
sion of ApoM in LDL-receptor knockout mice protects
against atherosclerosis in mice fed a cholesterol-rich diet.
These findings indicate that ApoM is important for preβ-
HDL formation and may exert a protective effect on the
development and progression of atherosclerosis [8]. More-
over, evidence indicates that ApoM levels are possibly
regulated by several cytokines in the in the human HepG2
cell line, which was derived from hepatocellular carcinoma
[9-14]. However, the pathophysiological importance of
ApoM in humans is still unknown.
The androgen receptor (AR) is expressed in the liver,
the primary site of lipoprotein regulation, in which it could
conceivably alter the expression of genes controlling HDL
metabolism. Apolipoprotein AI (ApoAI) levels are reduced
after treatment with androgens, suggesting the decreased
synthesis or increased catabolism of this core constituent
of HDL particles [15,16]. ApoM, which is one of the main
constituents of HDL particles, is involved in HDL metab-
olism and formation of preβ-HDL. Whether androgens
regulate the secretion of apoM and further mediate lipid
metabolism remains unknown.
To further understand the possible effect of androgens
on ApoM secretion, we investigated the effects of 5-dihydrotestosterone (DHT) on the regulation of ApoM
expression by HepG2 cells. DHT is a potent natural an-
drogen that, unlike testosterone, cannot be converted to
estradiol by aromatase.
Results
Effects of DHT on ApoM mRNA levels and secretion of
ApoM by HepG2 cells
We first investigated whether DHT could modulate the
levels of ApoM mRNA and ApoM secretion from HepG2
cells. As shown in Figure 1, DHT significantly inhibited
secretion and mRNA levels of ApoM. At 10 nM DHT,
ApoM secretion was decreased by 20% (P < 0.05), and at
1000 nM DHT, ApoM secretion was decreased by 60%
(P < 0.01) compared with the control media (A). To test
the specificity of the effect of DHT on ApoM secretion,
we determined the effect of DHT on ApoAI secretion in
the same cell culture supernatants. DHT did not affect
ApoAI secretion at any concentration tested within the
levels of detection of the assays (B). DHT also signifi-
cantly suppressed the levels of ApoM mRNA expression
in a dose-dependent manner. At 10 nM, the reduction
in ApoM mRNA was about 20%, and at 1000 nM, it was
reduced by more than 70% (P < 0.01) compared with
control cells (C). However, the levels of ApoAI mRNA
were not affected by any concentration of DHT (D).
DHT-suppressed secretion and the mRNA levels of ApoM
are not blocked by flutamide
To test if the effect of DHT on ApoM secretion and ApoM
mRNA levels is mediated by the classical androgen recep-
tor, we performed incubations in the presence or absence
of the androgen receptor antagonist, flutamide (Figure 2).
After 30 min of incubation with flutamide, HepG2 cells
were incubated with different concentrations of DHT for
24 h, thereby resulting in the suppression of the secretion
of ApoM (A) and the levels of ApoM mRNA (B) in a dose-
dependent manner. This demonstrated that flutamide did
not change the effects of DHT on ApoM secretion or
ApoM mRNA levels, although HepG2 cells express the
classical androgen receptor.
PKC is involved in DHT-mediated apoM secretion
The PKC superfamily comprises 9 protein kinases. To de-
termine whether PKC is involved in DHT-mediated ApoM
secretion, HepG2 cells were incubated with PMA or Staur-
osporine in the presence or absence of DHT (Figure 3).
PMA decreased the expression and secretion of ApoM
(Figure 3A, C). Staurosporine alone had no effect on
the levels of ApoM and ApoM mRNA (Figure 3B, C).
Staurosporine abolished the DHT-mediated decrease in
ApoM secretion and expression (Figure 3D, E). These
results indicate that PKC affects the DHT-mediated
decrease in ApoM secretion and ApoM mRNA expression.
Figure 1 Effect of DHT on secretion and expression of ApoM and ApoAI. HepG2 cells were incubated in 2 ml of DMEM containing 10% FBS
until subconfluency was achieved. Medium was then changed to 2 ml of medium containing 10% CTFBS and various concentrations of DHT (0, 1,
3, 10, 30, 100, 300, 1000, 10000nM) and incubated for 24 h. ApoM and ApoAI levels were determined by western blotting analysis (A, B), ApoM
and ApoAI mRNA levels were determined by RT-PCR (C, D) as described in “Materials and methods.” Data are expressed relative to the control
group (100%). Data are represented as means ± S.D. (n = 6 for each sample group). Lane 1, control group, lanes 2–9, DHT concentrations of 1, 3,
10, 30, 100, 300, 1000 and 10000nM respectively. *P < 0.05 vs. control group.
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Figure 2 The effect of DHT on AapoM expression is independent of the classical androgen receptor. HepG2 cells were treated with
10 μM flutamide or vehicle for 30 min and then incubated in the presence of different concentrations of DHT for 24 h. ApoM concentrations
were determined by western blotting analysis (A), and ApoM mRNA levels were determined by RT-PCR (B) as described in “Materials and
methods.” Data are expressed relative to the control group (100%). Data are represented as means ± S.D. (n = 6 for each sample group). Lane 1,
control group, lanes 2–9, DHT concentrations of 1, 3, 10, 30, 100, 300, 1000 and 10000nM respectively. *,# P < 0.05 versus control group.
Yi-zhou et al. Lipids in Health and Disease 2012, 11:168 Page 4 of 10
http://www.lipidworld.com/content/11/1/168To determine whether PI3-K is involved in the DHT-
mediated reduction of ApoM secretion and the decrease
in the levels of its mRNA, HepG2 cells were also incu-
bated with the wortmannin, an inhibitor of PI3-K. The
PI3-K inhibitor wortmannin did not detectably alter the
effects of DHT on ApoM mRNA levels or its secretion
(data not shown).
Plasma ApoM and hepatic ApoM mRNA levels from mice
To analyze the effect of androgens on ApoM expression
and secretion, levels of plasma ApoM and liver ApoM
mRNA of DHT-treated mice were measured and com-
pared with those of vehicle-treated mice. Levels of
plasma ApoM was analyzed by Western Blot. Levels of
plasma ApoM were reduced in DHT-treated mice sig-
nificantly (Figure 4). Livers were frozen in liquid nitro-
gen for ApoM RNA analysis after mice were killed using
CO2. Levels ApoM mRNA were measured with RT-PCR.Levels of liver ApoM mRNA were reduced in DHT-
treated mice significantly (Figure 5).
Discussion
In the present study, we demonstrate that ApoM expres-
sion is regulated by DHT in HepG2 cells in a dose-
dependent manner and that inhibition of ApoM expression
by DHT is mediated by PKC. Moreover, DHT did not affect
ApoAI expression and we demonstrated further that inhib-
ition of PI3K did not influence DHT-mediated apoM
expression.
Androgens administration lowers HDL-C levels in
both genders [1], but androgens modulate cholesterol
metabolism in poorly understood ways. Most studies in-
dicate that administration of natural or synthetic andro-
gens produces a plethora of effects, some of which
appear negative, such as reduction of HDL-C levels, and
others positive, such as increased lean mass and reduced
Figure 3 The effect of DHT on the secretion of ApoM secretion and the levels of ApoM mRNA are mediated by PKC pathways. Cells
were treated with different concentrations of PMA or Staurosporine or vehicle (control) for 24 h, the levels of ApoM mRNA were determined by
RT-PCR (A,B). Cells were treated with 5 μM PMA or 50nM Staurosporine or vehicle for 24 h, ApoM concentrations were determined by western
blotting analysis (C). Cells were incubated in 1 μM DHT for 24 h in present different concentrations of Staurosporine or absent Staurosporine
(control). ApoM concentrations were determined by western blotting analysis (D), Lane 1, control group(1 μM DHT without Staurosporine), lanes
2–5, 1 μM DHT with Staurosporine concentrations of 1,5, 50, and 100 nM respectively. The levels of ApoM mRNA were determined by RT-PCR as
described in “Materials and methods.” Data are expressed relative to the control group (100%). Data are represented as means (SD) (n = 6 for
each sample group). *, P < 0.05 vs. control group. ***, P < 0.01 vs. control group.
Figure 4 Effect of DHT on plasma ApoM of DHT-treated C57BL/6 J mice. C57BL/6 J female mice were ovariectomized at the age of
3 months and treated at the age of 7 months. Animals were randomized into four groups (n = 6), with two groups receiving vehicle (propylene
glycol) alone, and two groups receiving 3 mg/kg DHT. All animals were treated daily by sc injections for 7d or 14d, fasted overnight, and killed
using CO2. Levels of plasma ApoM were determined by Western blotting as described in “Materials and methods.” Data are expressed relative to
the vehicle-treated group (100%). Data are represented as means ± S.D. (n = 6 for each treated group). Lane 1, vehicle-treated mice for 7d, Lane
2, DHT-treated mice for 7d, Lane 3, vehicle-treated mice for 14d and Lane 4, DHT-treated mice for 14d. Significant differences were determined
using ANOVA. *P < 0.05 vs. vehicle-treated mice, ***, P < 0.01 vs. vehicle-treated mice.
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Figure 5 Effect of DHT on liver ApoM mNRA of DHT-treated
C57BL/6 J mice. C57BL/6 J female mice were ovariectomized at the
age of 3 months and treated at the age of 7 months. Animals were
randomized into four groups (n = 6), with two groups receiving
vehicle (propylene glycol) alone, and two groups receiving 3 mg/kg
DHT. All animals were treated daily by sc injections for 7 or 14 d,
fasted overnight, and killed using CO2. Livers were frozen in liquid
nitrogen for ApoM RNA analysis. The levels of ApoM mRNA were
determined by RT-PCR as described in “Materials and methods.” Data
are expressed relative to the vehicle-treated group (100%). Data are
represented as means ± S.D. (n = 6 for each treated group).
Significant differences were determined using ANOVA. *P < 0.05 vs.
vehicle-treated mice, ***, P < 0.01 vs. vehicle-treated mice.
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tivity to insulin [17]. To understand the role of endogen-
ous and therapeutic androgens in CVD, it will be
necessary to identify the mechanisms responsible for the
reduction in HDL-C. One hypothesis considers reduced
synthesis of ApoAI, ApoM, or HDL. The second hypoth-
esis considers that there is decreased donation of choles-
terol from peripheral tissues to HDL particles, and the
third proposes that there is increased clearance of HDL-C.
The fourth, a more complex hypothesis, is that androgens
lead to HDL remodeling [15,18], cholesterol redistribution
[19], or changes in lipoprotein catabolism.
ApoAI and apoM are constituents of HDL. In some
studies, ApoAI levels are reduced after androgen treat-
ment, suggesting decreased synthesis or increased catabol-
ism of HDL [15,16]. ApoM was first identified as a
component of human postprandial lipoproteins in 1999
[4]. It was estimated that ~5% of HDL particles contain
ApoM [20]. ApoM content in the healthy human plasma
pool was 0.94 mM. This roughly corresponds to 1/50th of
the mean molar concentration of apoA-I in plasma [21].
However, the physiopathological functions of ApoM are
not fully elucidated. Studies of the regulation of ApoM ex-
pression may reveal the clinical importance of ApoM.
The AR is highly expressed in adipocytes and regulates
their function by a variety of mechanisms, including
local transcriptional regulation of lipases and increased
levels of adrenergic receptors as well as inhibition of adi-
pogenesis [19]. The AR is also expressed in liver, a pri-
mary site of lipoprotein regulation, in which it could
conceivably alter the expression of genes controlling
HDL metabolism [22]. ApoM is mainly expressed in the
hepatocytes. Here, we administered DHT to examine itseffect on ApoM secretion and ApoM mRNA levels in
HepG2 cells. The present study supports the view that
DHT affects lipoprotein production by demonstrating
that DHT significantly decreased ApoM mRNA levels in
hepG2 cells and the secretion of ApoM secretion into
the medium, whereas there was no effect on the ApoAI
mRNA levels. These findings suggest that there are dif-
ferent mechanisms for regulating ApoAI and ApoM ex-
pression in this particular cell line. To analyze the effect
of androgens on ApoM expression and secretion in vivo,
we administrated DHT to the ovariectomized C57BL/6 J
mice. Plasma levels of ApoM and liver ApoM mRNA of
DHT-treated mice were measured and compared with
those of vehicle-treated mice. It demonstrated that DHT
reduced the levels of plasma ApoM and liver ApoM
mRNA in DHT-treated mice. The present findings,
therefore, might partially indicate a mechanism under-
lying the reduction of plasma HDL cholesterol during
administration of DHT in vivo.
Sphingolipids are a large family of glycolipids and phos-
pholipids that share a common sphingoid base backbone.
These once called ‘structural’ lipids are now well-
established signaling molecules that play multiple roles in
a vast number of cellular processes. A growing body of lit-
erature has demonstrated the reciprocal interaction be-
tween bioactive sphingolipids and steroid hormones.
Sphingolipids serve as second messengers in steroidogenic
regulatory pathways [23,24], and meanwhile steroid hor-
mones regulates the metabolism of sphingolipids [25-27].
Plasma sphingosine-1-phosphate (S1P), which maintains
vascular integrity, is associated with HDL (∼65%) and al-
bumin (∼35%) [28,29]. HDL induced vasorelaxation as
well as barrier-promoting and prosurvival actions on the
endothelium have been attributed to S1P signaling
[30-32]. ApoM is a lipocalin that resides mainly in the
plasma HDL fraction [4]. The retained hydrophobic
NH2-terminal signal peptide anchors ApoM in the
phospholipid layer of the lipoprotein and prevents filtra-
tion of the ∼ 22-kDa protein in the kidney [33]. Studies in
ApoM gene-modified mice suggest that apoM has anti-
atherogenic effects, possibly related in part to ApoM’s
ability to increase cholesterol efflux from macrophage
foam cells, to increased preβ-HDL formation, and to anti-
oxidative effects [8,20,34]. ApoM is a carrier of S1P in
HDL and the HDL-associated ApoM–S1P complex med-
iates vasoprotective actions on the endothelium. This sig-
naling axis may be critical in normal vascular homeostasis
and perturbed in vascular diseases [35]. Whether DHT
affected HDL-associated function via regulation of ApoM
and ApoM–S1P signaling axis is still to be elucidated.
It is well known that androgens exert both transcrip-
tional and non-transcriptional actions [36-38]. The tran-
scriptional actions of androgens are mediated through
the classic androgen receptor. The ligand-bound classic
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factor modulating the expression of androgen-receptor
target genes. In contrast, non-transcriptional actions of
androgens include increasing the concentration of intra-
cellular calcium, and activation of protein tyrosine kin-
ase, such as Src(c-Src), extracellular signal-regulated
kinase-1/2 (ERK-1/2), and phosphatidylinositol 3-kinase
(PI3K) [39-44]. In our present study, we found that flu-
tamide, a classical androgen receptor blocker, did not
modify DHT-mediated apoM secretion. Although these
data may suggest that the action of DHT on ApoM se-
cretion is non-transcriptional, the differentiation be-
tween non-transcriptional vs. transcriptional effects is
much more complex and cannot been firmly concluded
from the present study.
We also investigated the intracellular signaling mechan-
isms by which DHT mediates ApoM secretion by hepG2
cells. Our present study shows that PMA, a PKC agonist,
increased ApoM secretion. Staurosporin, a PKC superfam-
ily inhibitor, abolished the DHT-mediated decrease in
ApoM secretion. The intracellular signaling mechanisms
by which DHT act through PKC to affect apoM secretion
remains unknown. It is reported that ApoM gene expres-
sion is affected by nuclear receptors such as hepatocyte
nuclear factor-1a (HNF-1a) [45], hepatocyte nuclear
factor-4a (HNF-4a), liver receptor homolog-1 (LRH-1)
[46], and liver X receptor (LXR) [47].
Leptin is the first identified endocrine product of adi-
pose tissue and was found to regulate vascular function
through local and central mechanisms [48]. There is some
evidence supporting the effects of leptin on the cardiovas-
cular system and Type 2 diabetes mellitus (T2DM). It was
shown that a high leptin level predicts subsequent devel-
opment of T2DM [49]. Plasma leptin levels positively cor-
related with TG, Lp (a), Apo-A1, glucose, BMI, insulin
resistance (HOMA-IR), SBP and DBP levels and negatively
with HDL-C levels in T2DM patients [50,51]. Studies sug-
gest that both leptin and leptin-receptor are essential for
ApoM expression in vitro and vivo [9,52]. In the present
study we demonstrated that DHT down-regulated the ex-
pression and the secretion of ApoM. Whether DHT-
affected ApoM expression is mediated by specific nuclear
receptors or leptin remains to be investigated.
It has been previously reported that ApoM expression
is regulated by PI3-kinase in HepG2-cells [53]. In the
present study, we used the PI3-K antagonist (wortman-
nin) to study DHT-treated HepG2 cells. We found that
wortmannin could not abolish DHT-mediated inhibition
of ApoM expression, which indicates that PI3-K might
not be involved in the DHT-induced inhibition of ApoM
expression. Our present results indicate that PKC is
involved in DHT-mediated ApoM secretion. However,
the participation of PKC family members whose iden-
tities remain to be determined.Conclusions
DHT directly and selectively down-regulated the level
of ApoM mRNA and the secretion of ApoM by protein




The human cell line HepG2, which was derived from hepa-
tocellular carcinoma, was obtained from the American
Type Culture Collection (ATCC). Dulbecco's modi-
fied Eagle's medium (DMEM) and benzylpenicillin and
streptomycin from Gibco (Shanghai, China). Dihydrotes-
tosterone (DHT) and flutamide were purchased from
Sigma Chemical Co. Ltd. (Shanghai, China). Staurospor-
ine, PMA and wortmannin were purchased from ENZO
(Shanghai, China). Six-well cell culture clusters and 25-cm2
vented cell culture flasks were purchased from Costar
(Shanghai, China). Fetal bovine serum (FBS) and charcoal-
treated fetal bovine serum (CTFBS) were obtained from
Invitrogen (Shanghai, China). E.Z.N.A. Total RNA Kit II
for total RNA purification was from Omega (Shanghai,
China). First strand cDNA synthesis kits were obtained
from Invitrogen (Shanghai, China). Taqman Universal
PCR Master Mix was purchased from TAKARA Bio-
Science and Technology Company (Dalian, China). The
LightCycler real-time RT-PCR System was purchased from
Roche Applied Science (Shanghai, China). Rabbit mono-
clonal antibodies against human ApoM, ApoAI, β-actin,
and horseradish peroxidase-conjugated goat polyclonal
secondary antibody to rabbit IgG (ab6721) were obtained
from Abcam.
Cell cultures
HepG2 cells were maintained in DMEM with 10% FBS
(w/v) in the presence of benzylpenicillin (0.1 iu l-1) and
streptomycin (0.1 g l-1) under standard culture condi-
tions (5% CO2, 37°C). Cells were seeded in 25-cm
2 cell
culture flasks or in 6-well cell-culture clusters and
allowed to grow to 50–70% confluence. Before the ex-
periment, cells were washed twice with phosphate buf-
fered saline (PBS) and once with DMEM with 10%
CTFBS(w/v). When inhibitors were used, they were
added in fresh media 30 min prior to adding the other
reagents. At the end of the incubation period, media
were removed and saved for ApoM and ApoAI assays
and the cells for determining ApoM and ApoAI mRNA
levels.
Effect of the androgen receptor antagonist flutamide on
DHT-mediated ApoM secretion and ApoM mRNA levels
To evaluate whether the effect of DHT on ApoM mRNA
levels and the secretion of ApoM from HepG2 cells was
mediated via the androgen receptor, cells were incubated
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was changed when the cells grew to subconfluence, and
flutamide (10 μM) was then added to the media. After
30 min of incubation with flutamide, different concen-
trations of DHT were added, and the media and cells
were harvested 24 h later for determining ApoM or
ApoAI levels.
Effect of protein kinase C or phosphatidylinositol 3-kinase
on DHT-mediated ApoM secretion and ApoM mRNA levels
To evaluate whether the effect of DHT on ApoM secre-
tion from human HepG2 cells was mediated via protein
kinase C (PKC), cells were incubated with agonist or an-
tagonist of PKC in the presence or absence of DHT. The
medium was changed at subconfluence, after 30 min of
incubation with an antagonist of the PKC superfamily
(staurosporine, 50 nM) or agonist of PKC (PMA), vary-
ing concentrations of DHT were added, and media and
cells were harvested 24 h later for the determination of
ApoM or ApoAI levels.
To evaluate whether the effect of DHT on ApoM
secreted by HepG2 cells was mediated via phosphatidyli-
nositol 3-kinase (PI3-K), cells were incubated in the
presence or absence of an inhibitor of PI3-K (wortmannin).
After 30 min of incubation with wortmannin (50 nM),
different concentrations of DHT were added, and the
media and cells were harvested 24 h later for the deter-
mination of ApoM.
Mice
C57BL/6 J female mice were obtained from the Experi-
mental Animal Center of the Chinese Academy of
Sciences (Shanghai, China) and maintained in a 12-h/12-
h light/dark cycle with unlimited access to chow and
water. Mice were ovariectomized at the age of 3 months
and treated at the age of 7 months. Animals were rando-
mized into four groups (n = 6), with two groups receiv-
ing vehicle (propylene glycol) alone, and two groups
receiving 3 mg/kg DHT. All animals were treated daily
by sc injections for 7 d or 14 d, fasted overnight, and
killed using CO2. Plasmas were collected for ApoM ana-
lysis, and livers were frozen in liquid nitrogen for ApoM
RNA analysis.
Extraction of total RNA and real time RT-PCR assays
Total HepG2 RNA of was extracted using the E.Z.N.A.
Total RNA Kit II according to the manufacturer’s instruc-
tions. For reverse transcription 5 μg total RNA was incu-
bated with 0.5 μg T12VN and Superscript III following the
manufacture’s suggested protocol. Human ApoM primers
(forward: 50-TACCAGCCCTTCTGCACTG-30, reverse:
50-ATCGAGGGAAGAGTGGGG-30) and human ApoAI
primers (forward: 50-GGCTGTCATCTCTCAGGGAGTT
AG-30, reverse: 50-ATTTGAACCTGCCTGACCCTTAG-30)and β-actin primers (forward: 50- ACTTACGGTAAA
TGGCCCG −30, reverse: 50- TAGGGGGCGTACTTGG
CATA −30) and mouse ApoM primers (forward: 50-
CCAAATAGGCTGTCCCAGAA-30, reverse: 50-CGAGTC
ACTTTCCTGGCTTC-30) were designed with Primer Ex-
press software (Applied Biosystems). Quantification of
ApoM mRNA levels or ApoAI mRNA levels is relative to
β-actin mRNA levels and was performed on a LightCycler
in a final volume of 20 μl. Optimal conditions were obtained
with 2.0 μl of Taqman Universal PCR Master Mix, 22.5 pmol
of both forward and reverse primers and 1 μl of RT product.
The thermal cycling conditions for human or mouse ApoM,
ApoAI, and β-actin included the following steps: 2 min at
50°C and 1 min 95°C to activate Taq polymerase, 40 cycles
of 15 sec at 95°C and 1 min at 60°C. Samples were amplified
simultaneously in triplicates in one-assay run. The threshold
cycle (CT) is defined as the fractional cycle number at which
the reporter fluorescence reaches a certain level. The ratio
expression of each gene in experimental vs. control samples
was calculated as 2-(meanΔΔCt). Significant differences were
determined using ANOVA.Apolipoproteins M and AI protein mass determinations
The relative molecular masses of ApoM and ApoAI
were determined by western blotting analysis. Cell cul-
ture medium containing CTFBS or plasma from mice
was fractionated by SDS-polyacrylamide gel electrophor-
esis, and the proteins were transferred to a nitrocellulose
membrane, which was incubated with rabbit monoclonal
antibodies and goat polyclonal secondary antibody.
Bands corresponding to the different apolipoproteins
were visualized using an ECL Plus Western blotting de-
tection system (GE Healthcare Life Science) or using the
peroxidase staining method and quantified using Quan-
tity One software.Statistical analysis
Results are expressed as means ± S.D. Two groups were
compared using Student’s t-test, and multiple groups were
analyzed by factorial ANOVA followed by Newman-Keuls’
post hoc comparisons. Statistical calculations were per-
formed with Statistical software package version 7.1. Dif-
ferences were considered significant at P < 0.05.
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